Skip to main content
TipRanks
Go Ultimate75% OFF

Radiopharm Theranostics Limited Sponsored ADR (RADX) AI Stock Analysis

65 Followers
RADX

Radiopharm Theranostics Limited Sponsored ADR

(NASDAQ:RADX)

Select Model
Rating:42Neutral
Price Target:$0.76▼(-0.26% Downside)
Action:reiterated
Date:11/13/26

The score is primarily held down by weak financial performance (widening losses and rising cash burn) and bearish technicals (price far below major moving averages with negative MACD). Valuation provides limited support due to loss-making status (negative P/E) and no dividend yield data.

Positive Factors
Debt-free balance sheetThe absence of debt limits mandatory interest and principal payments, giving Radiopharm greater flexibility while it develops its pipeline. This structure can help preserve strategic options and reduce insolvency pressure compared with a similarly loss-making biotech carrying material leverage.
Negative Factors
Persistent cash burnSustained and increasing operating cash outflows require Radiopharm to secure external funding unless profitability improves materially. That dependence can constrain development choices, increase financing uncertainty, and raise the potential for shareholder dilution during continued clinical investment.

Radiopharm Theranostics Limited Sponsored ADR (RADX) vs. SPDR S&P 500 ETF (SPY)

-100%-50%0%50%100%150%RADX-82.33%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$979.03K
Dividend Yield
―
Average Volume (3M)
57.95K
Price to Earnings (P/E)
-0.3
Beta (1Y)
0.99
Revenue Growth
-19.76%
EPS Growth
8.58%
Country
US
Employees
14
Sector
General
Sector Strength
55
Industry
Biotechnology

Radiopharm Theranostics Limited Sponsored ADR Business Overview & Revenue Model

Company Description

Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating pro...

Radiopharm Theranostics Limited Sponsored ADR Financial Statement Overview

Summary

Despite revenue growth off a small base, profitability is severely negative with gross profit turning negative and operating losses widening. Operating cash flow remains deeply negative with increasing burn, raising funding/dilution risk. The main offsetting strength is a debt-free balance sheet, but equity declined meaningfully, reflecting ongoing losses.

Income Statement

12Very Negative

Balance Sheet

56Neutral

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMJun 2025Jun 2024Jun 2023Jun 2022Jun 2022
Income Statement
Total Revenue2.76M2.71M3.63M299.23K8,831292.36K
Gross Profit-1.07M-2.10M39.28K299.23K8,831292.36K
EBITDA-69.12M-64.09M―-44.21M-17.96M-31.24M
Net Income-55.05M-53.94M-38.34M-47.95M-30.34M-34.61M
Balance Sheet
Total Assets60.14M60.14M86.48M72.04M83.38M74.95M
Cash, Cash Equivalents and Short-Term Investments4.14M4.14M29.12M18.58M26.98M11.70M
Total Debt000000
Total Liabilities37.81M37.81M43.61M44.68M20.42M29.37M
Stockholders Equity24.69M24.69M44.79M28.12M62.96M44.38M
Cash Flow
Free Cash Flow-22.26M0-36.65M-22.98M-38.25M-24.73M
Operating Cash Flow-54.34M-51.63M-36.65M-22.98M-9.92M-23.20M
Investing Cash Flow-5.69M-5.30M1.77M-320.00K-28.37M-1.53M
Financing Cash Flow35.04M32.65M45.43M30.20M65.11M9.22M

Radiopharm Theranostics Limited Sponsored ADR Technical Analysis

Technical Analysis SentimentNegative
Last Price0.76

Price Trends

50DMA1.29Negative
100DMA2.32Negative
200DMA3.47Negative

Market Momentum

MACD-0.14Negative
RSI30.97Neutral
STOCH8.36Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RADX, the sentiment is Negative. The current price of 0.76 is below the 20-day moving average (MA) of 0.93, below the 50-day MA of 1.29, and below the 200-day MA of 3.47, indicating a bearish trend. The MACD of -0.14 indicates Negative momentum. The RSI at 30.97 is Neutral, neither overbought nor oversold. The STOCH value of 8.36 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RADX.

Radiopharm Theranostics Limited Sponsored ADR Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

RADX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
ACRVACRV52Neutral$62.14M-0.77-70.14%――16.04%
RADXRADX42Neutral$12.76M-0.26-144.24%―-19.76%8.58%
CELUCELU40Underperform$20.45M-0.35142.25%―-58.14%47.25%
SERSER40Underperform$36.93M-0.79-195.03%―――

* General Sector Average

Performance Comparison

-50%0%50%100%RADXSERCELUACRVTELODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
RADX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
RADXRadiopharm Theranostics Limited Sponsored ADR0.76-3.76-83.19%
SERSerina Therapeutics, Inc.1.39-2.43-63.58%
CELUCelularity Inc.0.63-0.89-58.55%
ACRVAcrivon Therapeutics, Inc.1.45-0.93-39.08%
TELOTelomir Pharmaceuticals, Inc.0.49-0.91-65.00%

Radiopharm Theranostics Limited Sponsored ADR Corporate Events

Radiopharm Theranostics Publishes Four Director Interest Notices

Nov 12, 2026

On November 11, 2026, Radiopharm Theranostics Limited published an Australian Securities Exchange announcement titled “Change of Director’s Interest Notices x 4.” The notices reported that directors Bruce Goodwin and Ian Turner each disposed of 1,061...

Radiopharm Theranostics to Present Positive RAD101 Phase 2b Brain Metastases Data at SNO 2026

Sep 14, 2026

On September 14, 2026, Radiopharm Theranostics announced that interim data from its U.S. Phase 2b imaging trial of 18F-RAD101 in suspected recurrent brain metastases have been selected for a late-breaking oral presentation at the Society of Neuro-Onc...

Radiopharm Theranostics Posts Deeper FY26 Loss as R&D Spend Jumps and Cash Reserves Fall

Aug 28, 2026

Radiopharm Theranostics Limited has reported a sharply wider loss for the year ended 30 June 2026, as it stepped up investment in clinical development of its radiopharmaceutical pipeline. Revenue from contracts with customers fell 23.8% to $2.77 mill...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026